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Sanders et al. (2014) demonstrate in this issue ofNeuron that the natively unfolded protein tau can propagate
indefinitely in distinct stable strains, therefore supporting the general idea that tau has prion-like properties,
with implications for Alzheimer’s disease and other tauopathies.Tau is a microtubule-associated pro-
tein that is generally considered to be
‘‘unfolded’’ in its native state (Schwalbe
et al., 2014), although it clearly adopts
specific conformations when associated
with microtubules, or when it is ‘‘mis-
folded’’ in the setting of forming inclusions
in neuronal soma as neurofibrillary tan-
gles in Alzheimer’s disease or as different
inclusions in other tauopathies. Morpho-
logically, these various tauopathies are
distinct, allowing neuropathologists to
readily distinguish the tangles of Alz-
heimer’s disease from Pick bodies
in frontotemporal dementia or argyro-
phillic grains in argyrophillic grain dis-
ease (Feany and Dickson, 1996). How
these different morphologies arise from
the same protein has been uncertain,
although in any individual patient one
type of morphology tends to predomi-
nate. In addition to the differences in
morphology, the various types of inclu-
sions are also differentiated by the spe-
cific neuronal populations and even brain
areas affected and often by the isoform
(e.g., 4 repeat versus 3 repeat tau) and
phosphorylation state of tau. Both genetic
(mutation and splice form changes) and
sporadic forms of tauopathies occur,
each with a characteristic neuroanatom-
ical pattern of ‘‘spread’’ (Arnold et al.,
2013). Some of the disorders classi-
cally are strikingly asymmetric, strongly
affecting either the right or left hemi-
sphere, another puzzling characteristic
especially in instances where the cause
is genetic.
The current exciting study by Sanders
et al. (2014), building on elegant work by
Clavaguera and colleagues (Clavaguera
et al., 2013), addresses some of these
issues. The data suggest that one waythese morphological and clinical variants
occur is through propagation of individual
‘‘strains’’ of misfolded tau. They demon-
strate that tau can adopt different
conformational states and that those
conformational states are stable and can
be propagated by recruitment of native
tau to indefinitely cause new inclusions
to form in inoculated cells in culture, or
predisposed neurons in brain, over multi-
ple rounds of seeding and spreading.
Distinct strains can be obtained by clonal
selection in vitro or by utilizing tau derived
from human tauopathy cases of various
diseases, in each case showing stable
conformational integrity analogous to
prion ‘‘strains.’’ This supports the notion
that tau has prion-like properties, since
the formation of conformationally stable
strains is a property of other prion-like
molecules. Moreover, the data demon-
strate that different conformations can
occur in different pathological settings
and therefore imply that these conforma-
tions might account for the different clin-
ical and neuropathological characteristics
of the various tauopathies.
Another example of templated misfold-
ing of tau seems to occur in the observed
transsynaptic spread of the presumed
pathogenic species in mouse models (de
Calignon et al., 2012; Liu et al., 2012);
this has been suggested as the underlying
mechanism of the march of tau neuro-
fibrillary tangles from limbic areas to
broader neocortical targets in a hierarchi-
cal pattern across anatomically distinct
pathways in Alzheimer’s disease. Impor-
tantly, in humans the data suggest that
the transsynaptic spread phenomenon is
a combination of the presence of specific,
unique characteristic tau conformers and
a recipient neuron that can act as theNeuron 8host. For example, while many of the hip-
pocampal neurons that develop neuro-
fibrillary tangles in Alzheimer’s disease
are strongly interconnected, dentate gy-
rus granule cells, which receive the bulk
of the perforant pathway projection from
the early affected entorhinal cortex, are
relatively resistant (Hyman et al., 1984).
On the other hand, tau inclusions called
Pick bodies are classically present in fron-
totemporal dementia, despite the fact
that it is exactly these same granule cells
in the dentate gyrus that are resistant to
the alternatively folded form of tau found
in neurofibrillary tangles. The observa-
tion of distinct strains in tauopathies that
have differential cellular and brain region
predispositions suggest unique relation-
ships between specific misfolded tau
species and host cell characteristics that
are largely unexplored.
Many questions remain to be
answered, both in tauopathies and in the
broader context of prion disorders and
other neurodegenerative diseases. How
are different ‘‘strains’’ initiated in individ-
ual patients with different diseases? Why
would different brain areas and neuronal
subtypes be selectively vulnerable for
different forms of inclusions? What types
of insults might cause the initial misfolding
events that are then propagated across
neural systems? Why would this process
lead to a dramatically asymmetric pattern
of neurodegeneration in some diseases,
while others are quite symmetric? Why
would specific, and distinct, neural sys-
tems be involved based on the exact tau
‘‘strain’’ or conformation of the molecule?
How does themisfoldedmolecule escape
cellular surveillance mechanisms? Are
the misfolded tau molecules toxic, and
are various strains differentially toxic to2, June 18, 2014 ª2014 Elsevier Inc. 1189
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transcriptional (splicing) and posttransla-
tional alterations of tau fit into this newly
evolving view of tau’s conformational
complexity? And does tau toxicity occur
as a consequence of its accumulation in
the cell body as an aggregate, or perhaps
more directly as a synaptotoxic species
that is distinct from the aggregating forms
(Irwin et al., 2013; Tai et al., 2012)?
The current data clearly demonstrate
that tau can form strains that retain their
biological characteristics over succes-
sive inoculations and also that these
strains can induce inclusions in neurons,
so that misfolded tau appears to be trans-
missible both across the synapse within
a brain and also between brains. Tau
therefore shares important characteris-
tics of prions. However, there are critical
aspects of the data that imply differences
between tau biology and classical prion
diseases and suggest caution in interpret-
ing tau as an example of a prion, and, by
extension, tauopathies and Alzheimer’s
disease to be prion diseases in the way
that these terms are commonly used—
as communicable diseases. Importantly,
as noted by Sanders et al. (2014), infec-
tivity in humans has not been shown.
The species barrier present in so many
examples in prion disease appear not
to be the case for tau, which can recruit
endogenous mouse tau to mutant human
protein (de Calignon et al., 2012). Strictly
speaking, it is not yet clear that fibrillar1190 Neuron 82, June 18, 2014 ª2014 Elsevitau is neurotoxic, and instead either solu-
ble tau species, or mislocalized tau, have
been suggested to lead to neural impair-
ments (Frost et al., 2014; Kopeikina
et al., 2012; Kuchibhotla et al., 2014;
Kumar et al., 2014). Therefore, at this
point it appears that mechanisms of tau
fibril spread appear to share biological
systems analogous in many ways to prion
spreading, but it remains to be shown
whether tau has all prion-like proper-
ties—including human to human infec-
tivity, and toxicity, and thus whether it
should be considered a member of the
prion family of protein misfolding disor-
ders or a true prion disease. Nonetheless,
the current data strongly support the idea
that tau—and especially extracellular
tau—is a viable target for therapeutic in-
terventions (Yanamandra et al., 2013).REFERENCES
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